| Assay ID | Title | Year | Journal | Article |
|---|
| AID435968 | Percentage GSK3-beta activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID325630 | Inhibition of cRAF1 | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224773 | Delta TM value showing the stabilisation of ASK1 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID435119 | Percentage MKK1 activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID435341 | Percentage CHK2 activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID1224788 | Delta TM value showing the stabilisation of PIM3 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224757 | Delta TM value showing the stabilisation of CDK2 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID322453 | Inhibition of Raf1 kinase | 2008 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 18, Issue:7
| Pharmacophore identification of Raf-1 kinase inhibitors. |
| AID1224768 | Delta TM value showing the stabilisation of DMPK1 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID435459 | Percentage CK1delta activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID436064 | Percentage Aurora C activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID1224759 | Delta TM value showing the stabilisation of CDKL1 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID435542 | Percentage PKBbeta activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID241747 | Concentration required to inhibit human mitogen activated protein kinase p38 activity | 2004 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21
| A novel series of p38 MAP kinase inhibitors for the potential treatment of rheumatoid arthritis. |
| AID1224771 | Delta TM value showing the stabilisation of MEK2 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224753 | Delta TM value showing the stabilisation of CAMK2D produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID435840 | Percentage AMPK activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID1224802 | Delta TM value showing the stabilisation of TNIK produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID503304 | Antiproliferative activity against human PC3 cells at 5 uM after 120 hrs by MTT assay relative to DMSO | 2006 | Nature chemical biology, Jun, Volume: 2, Issue:6
| Identifying off-target effects and hidden phenotypes of drugs in human cells. |
| AID435628 | Percentage ROCK2 activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID435967 | Percentage ERK8 activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID1224793 | Delta TM value showing the stabilisation of RSK2a produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID436038 | Percentage PIM2 activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID435631 | Percentage RSK1 activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID435603 | Percentage HIPK3 activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID435745 | Percentage PLK1 activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID435580 | Percentage Aurora B activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID435426 | Percentage PKBalpha activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID435597 | Percentage DYRK1A activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID435172 | Percentage PAK6 activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID1224783 | Delta TM value showing the stabilisation of PAK6 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID435812 | Percentage PIM1 activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID1224769 | Delta TM value showing the stabilisation of GSK3B produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID435622 | Percentage p38delta activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID1224797 | Delta TM value showing the stabilisation of MPSK1 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID435824 | Percentage PKA activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID435852 | Percentage GAK activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID435483 | Percentage NEK2a activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID1224779 | Delta TM value showing the stabilisation of NEK6 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224755 | Delta TM value showing the stabilisation of CAMK4 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224767 | Delta TM value showing the stabilisation of DAPK3 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID248830 | Concentration required to inhibit lipopolysaccharide induced TNF-alpha release was determined in human peripheral blood mononuclear cells | 2004 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21
| A novel series of p38 MAP kinase inhibitors for the potential treatment of rheumatoid arthritis. |
| AID435113 | Percentage MAPKAPK2 activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID435993 | Percentage Src activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID435720 | Percentage ERK2 activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID436028 | Percentage PHK activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID435376 | Percentage RSK2 activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID1224798 | Delta TM value showing the stabilisation of DRAK1 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID435876 | Percentage PRAK activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID1434112 | Inhibition of 17-AAG-induced HSF1 pathway in human SKOV3 cells assessed as reduction in HSP72 induction preincubated for 1 hr followed by 17-AAG addition measured after 18 hrs by ELISA | 2017 | Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
| Discovery of a Chemical Probe Bisamide (CCT251236): An Orally Bioavailable Efficacious Pirin Ligand from a Heat Shock Transcription Factor 1 (HSF1) Phenotypic Screen. |
| AID435953 | Inhibition of RIP2 in the presence of 100uM ATP | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID1224784 | Delta TM value showing the stabilisation of PCTK1 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID435241 | Percentage Lck activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID1224765 | Delta TM value showing the stabilisation of CK1G2 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224786 | Delta TM value showing the stabilisation of PIM1 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224807 | Delta TM value showing the stabilisation of YSK1 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID435316 | Percentage MELK activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID1224795 | Delta TM value showing the stabilisation of SLK produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224805 | Delta TM value showing the stabilisation of VRK2 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID435494 | Percentage PRK2 activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID435495 | Percentage RIP2 activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID1224776 | Delta TM value showing the stabilisation of ERK3 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224775 | Delta TM value showing the stabilisation of ERK1 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID435455 | Percentage CDK2-cyclinA activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID435129 | Percentage PKD1 activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID435488 | Percentage p38beta activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID1224782 | Delta TM value showing the stabilisation of PAK5 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID435476 | Percentage MNK1 activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID435991 | Percentage SGK1 activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID436078 | Percentage DYRK2 activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID1716410 | Binding affinity to Nluc-tagged MAPK14 (unknown origin) expressed in HeLa cells assessed as percentage of stability at 10 uM incubated for 3 mins by isothermal NaLTSA assay (Rvb = 32 +/- 2.1 %) | 2018 | ACS medicinal chemistry letters, Jun-14, Volume: 9, Issue:6
| Homogeneous Assay for Target Engagement Utilizing Bioluminescent Thermal Shift. |
| AID435480 | Percentage MSK1 activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID435448 | Inhibition of B-Raf in the presence of 100uM ATP | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID1224761 | Delta TM value showing the stabilisation of CLK1 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID435884 | Percentage SmMLCK activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID1224781 | Delta TM value showing the stabilisation of PAK4 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224748 | Delta TM value showing the stabilisation of AMPKA2 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID435218 | Percentage CaMKKalpha activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID1224754 | Delta TM value showing the stabilisation of CAMK2G produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224785 | Delta TM value showing the stabilisation of PDK1 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224770 | Delta TM value showing the stabilisation of JAK1~B produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID237716 | Solubility was determined | 2004 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21
| A novel series of p38 MAP kinase inhibitors for the potential treatment of rheumatoid arthritis. |
| AID435844 | Percentage CaMK1 activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID1224751 | Delta TM value showing the stabilisation of CAMK2A produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID435308 | Percentage PKCalpha activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID513134 | Inhibition of c-Raf kinase | 2006 | Nature chemical biology, Jul, Volume: 2, Issue:7
| Rational design of inhibitors that bind to inactive kinase conformations. |
| AID1224760 | Delta TM value showing the stabilisation of CHEK2 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224780 | Delta TM value showing the stabilisation of OSR1 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224804 | Delta TM value showing the stabilisation of VRK1 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224794 | Delta TM value showing the stabilisation of RSK2b produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224750 | Delta TM value showing the stabilisation of CAMK1G produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID435668 | Percentage PAK5 activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID435368 | Percentage NEK7 activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID1224778 | Delta TM value showing the stabilisation of NEK2 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID435741 | Percentage PKCzeta activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID435173 | Percentage PDK1 activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID1224800 | Delta TM value showing the stabilisation of MST4 (2) produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID435971 | Percentage MAPKAPK3 activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID435843 | Percentage B-Raf activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID435726 | Percentage JNK2 activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID1224756 | Delta TM value showing the stabilisation of CAMKK2 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID435356 | Percentage IKK-beta activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID435367 | Percentage NEK6 activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID435977 | Percentage MNK2 activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID435121 | Percentage MST2 activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID325795 | Inhibition of SAPK2b/p38beta | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID237412 | Log D value at pH 7.4 | 2004 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21
| A novel series of p38 MAP kinase inhibitors for the potential treatment of rheumatoid arthritis. |
| AID1224774 | Delta TM value showing the stabilisation of p38beta produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID435240 | Percentage JNK3 activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID1224792 | Delta TM value showing the stabilisation of RIOK2 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224787 | Delta TM value showing the stabilisation of PIM2 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID435850 | Percentage DYRK3 activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID436067 | Percentage CaMKKbeta activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID240494 | Inhibition of protein kinase c-raf | 2004 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21
| A novel series of p38 MAP kinase inhibitors for the potential treatment of rheumatoid arthritis. |
| AID1224789 | Delta TM value showing the stabilisation of PLK1 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID435859 | Percentage JNK1 activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID1224801 | Delta TM value showing the stabilisation of MST1 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID435994 | Percentage SRPK1 activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID1224752 | Delta TM value showing the stabilisation of CAMK2B produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1716408 | Binding affinity to Nluc-tagged MAPK14 (unknown origin) expressed in HeLa cells assessed as change in melting temperature at 50 uM by isothermal NaLTSA assay | 2018 | ACS medicinal chemistry letters, Jun-14, Volume: 9, Issue:6
| Homogeneous Assay for Target Engagement Utilizing Bioluminescent Thermal Shift. |
| AID1224791 | Delta TM value showing the stabilisation of PRKACA produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID436073 | Percentage CSK activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID1224799 | Delta TM value showing the stabilisation of NDR1 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID435453 | Percentage c-Raf activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID1224772 | Delta TM value showing the stabilisation of MAP2K6 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID435705 | Percentage BRSK2 activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID436085 | Percentage HIPK2 activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID435126 | Percentage p38-gamma activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID435963 | Percentage CK2 activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID1224758 | Delta TM value showing the stabilisation of CDK6 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID435753 | Percentage S6K1 activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID1224766 | Delta TM value showing the stabilisation of CK1G3 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID325794 | Inhibition of SAPK2a/p38-alpha | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224803 | Delta TM value showing the stabilisation of PBK produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID436080 | Percentage ERK1 activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID1224762 | Delta TM value showing the stabilisation of CLK2 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224763 | Delta TM value showing the stabilisation of CLK3 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID435869 | Percentage p38alpha activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID435416 | Percentage PAK4 activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID435973 | Percentage MARK3 activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID435946 | Inhibition of c-Raf in the presence of 100uM ATP | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID243238 | Protein binding was determined in human | 2004 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21
| A novel series of p38 MAP kinase inhibitors for the potential treatment of rheumatoid arthritis. |
| AID1224806 | Delta TM value showing the stabilisation of VRK3 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID435966 | Percentage EF2K activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID1224764 | Delta TM value showing the stabilisation of CK1G1 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID435682 | Percentage PIM3 activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID1224796 | Delta TM value showing the stabilisation of LOK produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224777 | Delta TM value showing the stabilisation of MST4(1) produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID435313 | Percentage CHK1 activity remaining in the presence of 10uM inhibitor | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID1224749 | Delta TM value showing the stabilisation of CAMK1D produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID435949 | Inhibition of Lck in the presence of 50uM ATP | 2007 | The Biochemical journal, Dec-15, Volume: 408, Issue:3
| The selectivity of protein kinase inhibitors: a further update. |
| AID1224790 | Delta TM value showing the stabilisation of PLK4 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
| A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3
| High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID1345813 | Human Raf-1 proto-oncogene, serine/threonine kinase (RAF family) | 2003 | The Biochemical journal, Apr-01, Volume: 371, Issue:Pt 1
| The specificities of protein kinase inhibitors: an update. |
| AID1345813 | Human Raf-1 proto-oncogene, serine/threonine kinase (RAF family) | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
| Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |